CAS 65360-29-4 | GPX-150-004 : Camsirubicin
(World's Largest Pharmaceutical Supplier)
- CAS Number: 65360-29-4
- Stock: 999g
- Assay: 0.00%
CAS 65360-29-4, also known as mesalamine, is a medication used in the treatment of inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. It belongs to a class of drugs called 5-aminosalicylates, which work by reducing inflammation in the lining of the intestines.
Mesalamine was first approved for use by the United States Food and Drug Administration (FDA) in 1987, and has since become widely prescribed. It is typically taken orally or rectally, depending on the severity and location of the inflammation.
In addition to its primary use in treating IBD, mesalamine has also been investigated for its potential use in treating other conditions. For example, some studies have suggested that it may be beneficial in preventing colorectal cancer in patients with a history of IBD.
Like all medications, mesalamine can cause side effects. Some common side effects include headache, nausea, and diarrhea. In rare cases, it may also cause serious side effects such as kidney damage or pancreatitis.
Despite its potential side effects, mesalamine has been shown to be an effective treatment for IBD, helping to reduce inflammation and improve symptoms such as abdominal pain and diarrhea. As such, it is a valuable tool in the management of these chronic conditions, and continues to be an important area of research and development in the field of gastroenterology.